6 assets in Hypopharyngeal Carcinoma

Therapeutic assets addressing Hypopharyngeal Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Hypopharyngeal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Hypopharyngeal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)- Hypopharyngeal Carcinoma	VM Oncology, LLC	P1/2	CCC (48)
Docetaxel Hypopharyngeal Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (48)
Pembrolizumab Hypopharyngeal Carcinoma	VM Oncology, LLC	P1/2	CCC (48)
SX682 Hypopharyngeal Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (48)